Last update 21 Nov 2024

Tenofovir Alafenamide Fumarate/Elvitegravir

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
TAF/EVG, Tenofovir Alafenamide/Elvitegravir
Target
HIV integrase x RT
Mechanism
HIV-1 integrase inhibitors(HIV integrase inhibitors), RT inhibitors(Reverse transcriptase inhibitors)
Therapeutic Areas
Immune System DiseasesInfectious DiseasesUrogenital Diseases
Active Indication
HIV Infections
Inactive Indication-
Originator Organization
Eastern Virginia Medical SchoolEastern Virginia Medical School
Active Organization
Eastern Virginia Medical SchoolEastern Virginia Medical School
Inactive Organization
National Institute of Allergy & Infectious Diseases
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Structure

Molecular FormulaC23H23ClFNO5
InChIKeyJUZYLCPPVHEVSV-LJQANCHMSA-N
CAS Registry697761-98-1
View All Structures (2)

Related

2
Clinical Trials associated with Tenofovir Alafenamide Fumarate/Elvitegravir
NCT06274398 / RecruitingPhase 1IIT
A Double-Blind, Placebo-Controlled, Randomized Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Rectally Administered Tenofovir Alafenamide/Elvitegravir Inserts
NCT04047420 / CompletedPhase 1IIT
A Phase 1 Open Label Safety and Pharmacokinetic Study of Rectal Administration of a Tenofovir Alafenamide/Elvitegravir Insert at Two Dose Levels
100 Clinical Results associated with Tenofovir Alafenamide Fumarate/Elvitegravir
Login to view more data
100 Translational Medicine associated with Tenofovir Alafenamide Fumarate/Elvitegravir
Login to view more data
100 Patents (Medical) associated with Tenofovir Alafenamide Fumarate/Elvitegravir
Login to view more data
100 Deals associated with Tenofovir Alafenamide Fumarate/Elvitegravir
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
HIV InfectionsIND Application
US
National Institute of Allergy & Infectious Diseases
11 Dec 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT04047420 (MTN-039, Pubmed)
ManualManual
Phase 1
HIV Infections
-
(zldsyocawi) = yzchqbkfgh owfuzczoou (sgryosngcz )
View more
Positive
24 Apr 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free